Upregulated FKBP4 was only significantly related to worse survival in luminal A subtype patients (HR=1.38; 95%CI:1.12-1.70, p=0.0027), but not correlated to those in luminal B, HER2 positive and basal-like subtypes of breast cancer patients (HR=0.97; 95%CI:0.75-1.26, p=0.8098; HR=1.08; 95% CI:0.81-1.44, p=0.5835; HR=0.83; 95% CI:0.64-1.07, p=0.1539) (Figure 3E-3H). Here, FKBP4 is linked to breast carcinoma.